Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) Invested Capital (2018 - 2026)

Exagen filings provide 9 years of Invested Capital readings, the most recent being $37.3 million for Q1 2026.

  • On a quarterly basis, Invested Capital rose 42.36% to $37.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $37.3 million, a 42.36% increase, with the full-year FY2025 number at $39.1 million, up 36.69% from a year prior.
  • Invested Capital hit $37.3 million in Q1 2026 for Exagen, down from $39.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $103.8 million in Q1 2022 to a low of $26.2 million in Q1 2025.
  • Median Invested Capital over the past 5 years was $41.4 million (2023), compared with a mean of $51.8 million.
  • Biggest five-year swings in Invested Capital: crashed 44.23% in 2023 and later skyrocketed 42.36% in 2026.
  • Exagen's Invested Capital stood at $70.8 million in 2022, then plummeted by 41.5% to $41.4 million in 2023, then crashed by 30.81% to $28.6 million in 2024, then soared by 36.69% to $39.1 million in 2025, then dropped by 4.72% to $37.3 million in 2026.
  • The last three reported values for Invested Capital were $37.3 million (Q1 2026), $39.1 million (Q4 2025), and $41.1 million (Q3 2025) per Business Quant data.